Read this company snapshot
Daily valuation snapshot
Teva Pharmaceutical Industries Limited: source evidence dated 2026-10-09.
- Daily close (USD)
- $41.1
- Market capitalization (USD)
- $47,893,669,052.4
- Price / earnings (TTM)
- 67.74
- Price / book
- 6.17
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research TEVA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research TEVA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing TEVA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $41.1 |
| Market capitalization (USD) | $47,893,669,052.4 |
| Price / earnings (TTM) | 67.74 |
| Price / book | 6.17 |
No matching rows. Clear the filter to see all records.
Read TEVA's valuation metrics
Company size
Teva Pharmaceutical Industries Limited's recorded market capitalization is $47,893,669,052.4. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
TEVA's recorded P/E is 67.74: about $67.74 of share price for each $1 of trailing annual earnings per share. Compare that multiple with earnings growth and companies in the same business.
Price relative to book equity
TEVA's recorded price-to-book ratio is 6.17. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Teva Pharmaceutical Industries Limited with Aurora
Use the snapshot above to ask a specific question about TEVA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow TEVA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.